Susquehanna International Group’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $895K | Buy |
59,816
+1,120
| +2% | +$16.8K | ﹤0.01% | 3430 |
|
|
2025
Q1 | $947K | Buy |
58,696
+35,607
| +154% | +$575K | ﹤0.01% | 3435 |
|
|
2024
Q4 | $538K | Buy |
23,089
+9,891
| +75% | +$230K | ﹤0.01% | 3960 |
|
|
2024
Q3 | $388K | Buy |
+13,198
| New | +$388K | ﹤0.01% | 3980 |
|
|
2024
Q2 | – | Sell |
-101,503
| Closed | -$3.85M | – | 6566 |
|
|
2024
Q1 | $3.85M | Buy |
+101,503
| New | +$3.85M | ﹤0.01% | 1212 |
|
|
2023
Q3 | – | Sell |
-1,447
| Closed | -$16.3K | – | 6332 |
|
|
2023
Q2 | $16.3K | Buy |
+1,447
| New | +$16.3K | ﹤0.01% | 5381 |
|
|
2023
Q1 | – | Sell |
-2,038
| Closed | -$22.9K | – | 6677 |
|
|
2022
Q4 | $22.9K | Buy |
+2,038
| New | +$22.9K | ﹤0.01% | 5333 |
|
|
2022
Q3 | – | Sell |
-2,608
| Closed | -$33K | – | 6871 |
|
|
2022
Q2 | $33K | Buy |
+2,608
| New | +$33K | ﹤0.01% | 5326 |
|
|
2021
Q4 | – | Sell |
-448
| Closed | -$89K | – | 6431 |
|
|
2021
Q3 | $89K | Buy |
+448
| New | +$89K | ﹤0.01% | 5001 |
|
|
2021
Q1 | – | Sell |
-426
| Closed | -$84K | – | 5742 |
|
|
2020
Q4 | $84K | Sell |
426
-23
| -5% | -$4.54K | ﹤0.01% | 4532 |
|
|
2020
Q3 | $80K | Buy |
+449
| New | +$80K | ﹤0.01% | 4152 |
|
|
2020
Q2 | – | Sell |
-601
| Closed | -$70K | – | 4902 |
|
|
2020
Q1 | $70K | Buy |
+601
| New | +$70K | ﹤0.01% | 4132 |
|
|
2019
Q4 | – | Sell |
-625
| Closed | -$120K | – | 4775 |
|
|
2019
Q3 | $120K | Buy |
625
+142
| +29% | +$27.3K | ﹤0.01% | 4034 |
|
|
2019
Q2 | $83K | Buy |
+483
| New | +$83K | ﹤0.01% | 4196 |
|
|
2017
Q3 | – | Sell |
-6,800
| Closed | -$653K | – | 4164 |
|
|
2017
Q2 | $653K | Buy |
+6,800
| New | +$653K | ﹤0.01% | 2160 |
|